TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04518020

Intervention type: PROCEDURE
Group type: OTHER
Intervention: 40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA
Description: 40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
Study: NCT03056183

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Depression Care Transitions (DCT)
Description: DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
Study: NCT04518020

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 40 patients will be randomly allocated to short implants and standard implants in conjunction with MSFA
Description: 40 patients will be randomly allocated to short implants (group 1) and standard implants in conjunction with MSFA using 50% particulated autogenous mandibular bone graft mixed with 50% Bio-Oss (group 2).
Study: NCT04101370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosentan 125 mg
Description: Single administered dose of Bosentan (125 mg tablet immediate release) in a fasting condition

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tracleer 125Mg Tablet
Description: Single administered dose of Tracleer® (125 mg tablet immediate release) in a fasting condition
Study: NCT00663689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: erlotinib 150mg qd until disease progression or unacceptable toxicity.
Study: NCT00982748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pranayama (Yoga Breathing) Techniques
Description: 1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pranayama (Yoga Breathing) Techniques
Description: 1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
Study: NCT03871465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone SASD injection
Description: 2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Physiotherapy
Description: The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone injections & Physiotherapy
Description: 2ml triamcinolone (1ml/10mg) and 3ml 1% xylocain will be injected into the affected SASD bursa under ultrasound guidance.~The physiotherapy program consists of hot pack, interferential therapy, and exercise program, which includes stretch exercise, mobilization of the glenohumeral joint, manual pressure to the possible trigger points, scapular stabilization exercise, and strengthening exercise of the rotator cuff, trapezius, and serratus anterior muscles.
Study: NCT00763607

Intervention type: GENETIC
Intervention: Protein expression by immunohistochemistry and immunofluorescence
Description: Protein expression by immunohistochemistry and immunofluorescence
Study: NCT04129190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glucose
Description: Oral Intake of Glucose
Study: NCT00632515

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
Study: NCT04046601

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: impedance
Description: After endoscopic resection of early esophageal cancer, the tissue will be measured by an impedance probe between 10Hz-1000000Hz, 20mV. 8 gold electrodes have been integrated to the probe. The impedance will be measured in different ways between the elctrodes. There will be 10 measurements in total for each specimen.
Study: NCT00998036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Temsirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temsirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Temsirolimus will be given second over a 30 minute infusion during posthydration.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Temsirolimus 15mg~Dose Level 2: Temsirolimus 15mg~Dose Level 3: Temsirolimus 25mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin at 30mg/m2 will be administered intravenously weekly on days one and eight of a three week cycle. Cisplatin will be given first over a 30 minute infusion with prehydration.
Study: NCT00390559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo cigarette
Description: Non nicotine containing cigarette

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo cigarette
Description: Non nicotine containing cigarette
Study: NCT00998036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temsirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temsirolimus infusion.~Dose escalation will follow the standard 3 by 3 design with three set dosing levels.~Dose Level 1: Erlotinib 100mg~Dose Level 2: Erlotinib 150mg~Dose Level 3: Erlotinib 150mg
Study: NCT01787045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early and Active Physical Therapy
Description: Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.~Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc.
Study: NCT00642850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methoxy polyethylene glycol-epoetin beta [Mircera]
Description: 120, 200 or 360 micrograms iv monthly (starting dose)
Study: NCT01900249

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.2%
Description: R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R348 Ophthalmic Solution, 0.5%
Description: R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
Study: NCT01091649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: Low dose ABT-450 / ritonavir see Arm Description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: Low dose ABT-450 / ritonavir see Arm Description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: Low dose ABT-450 / ritonavir see Arm Description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: ritonavir see Arm Description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: ritonavir see Arm Description for more information
Study: NCT01787045

Intervention type: OTHER
Group type: OTHER
Intervention: Passive Range of Motion
Description: Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive Range of Motion
Description: Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
Study: NCT01462591

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-citrulline
Description: 2 weeks of L-citrulline supplementation (100mg/kg of body weight).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: L-citrulline
Description: 2 weeks of L-citrulline supplementation (100mg/kg of body weight).
Study: NCT00693420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.03% sterile solution
Description: Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle sterile solution
Description: Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
Study: NCT03849196

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl 10Mg Suppository
Description: bisacodyl 10 mg suppository

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1L PEG-Asc
Description: PEG-Asc powder
Study: NCT02063620

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine HCL
Description: ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
Study: NCT03932890

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Patient controlled fluid device administering high volume thirst guided fluid bolus
Description: The administration of a 200ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Patient controlled fluid device administering low volume thirst guided fluid bolus
Description: The administration of a 50ml fluid bolus in response to subjective thirst. Participant activates trigger in response to thirst which activates fluid pump to deliver 50ml IV fluid bolus of 4% dextrose \& 0.18% sodium chloride
Study: NCT04246268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVOcell
Description: Female participants undergoing in vitro fertilization (IVF) and/or Intracytoplasmic Sperm Injection (ICSI) for assisted reproduction will be asked to participate.
Study: NCT03338452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low energy ketogenic diet
Description: Low energy ketogenic diet lasting 12 weeks with a previous preparation period including detailed instructions during classes and individual counselling by a dietitian. Participants were provided with a list of suitable foods with very low carbohydrate content. Furthermore, the subjects shared cooking recipes and links to helpful webpages. They were free to follow a KD according to their personal preferences but limit their carbohydrate intake to 5-10 % of total energy from carbohydrates, but derive at least 70 % of total energy from fat.
Study: NCT01644019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Teleconsultation
Description: Teleconsultation of an EMS physician in cases of suspected acute stroke
Study: NCT03144089

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Articulated Oral Airway
Description: The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. The AOA will be evaluated for efficacy of mask ventilation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guedel oral airway (active comparator)
Description: The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. The Guedel oral airway will be evaluated for efficacy of mask ventilation.
Study: NCT03669146

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glasses
Description: Partial refractive correction in a pair of glasses.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glasses
Description: Partial refractive correction in a pair of glasses.
Study: NCT01784250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
Study: NCT01091649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: ritonavir see Arm Description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: ritonavir see Arm Description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ritonavir
Description: ritonavir see Arm Description for more information

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: High dose ABT-450 / ritonavir See Arm Description for more information
Study: NCT01784250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol
Description: Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill manufactured to mimic a drug
Study: NCT04197206

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: costotransverse block
Description: patient controlled analgesia devices with tramadol
Study: NCT05563259

Intervention type: RADIATION
Intervention: Cognitive assessment, functional magnetic resonance imaging
Description: Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition.

Intervention type: RADIATION
Intervention: Cognitive assessment, functional magnetic resonance imaging
Description: Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition.

Intervention type: RADIATION
Intervention: Cognitive assessment, functional magnetic resonance imaging
Description: Our study investigated cognitive function, MRI measures of brain structure and activation in patients undergoing liver biopsy. We aimed to evaluate the changes of cognition during the process of NAFLD and explore the association between brain alterations and cognition.
Study: NCT01711437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEG-4000 with citrates and simethicone
Description: 1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyethylene glycol 4000 solution with simethicon
Description: patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid
Description: patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
Study: NCT01091649

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ABT-450
Description: High dose ABT-450 / ritonavir See Arm Description for more information
Study: NCT00756405

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant diet
Description: Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Antioxidant supplement
Description: Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants were asked to consume their usual diet and take a placebo pill.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants were asked to consume their usual diet and take a placebo pill.
Study: NCT04926519

Intervention type: OTHER
Intervention: Type of periodontal treatment
Description: Identify factors that contribute to disease recurrence due to periodontal classification and periodontal treatment. One group have got the diagnosis aggressive periodontitis at baseline and the other group chronic periodontitis. Since 2018 we have the classification system with stage and grade.
Study: NCT01711437

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sodium picosulphate plus magnesium oxide and citric acid
Description: patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
Study: NCT00649610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: valdecoxib
Description: valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
Study: NCT03948139

Intervention type: DEVICE
Group type: OTHER
Intervention: Functional Brace
Description: The study will generate five standardized sized braces based on measurements from prior scans that will be stocked at each institution and modified by the local orthotist to fit the needs of each patient. This will facilitate expedited care while obtaining the same clinical and radiographic results as the fully customized braces. This idea has the potential to be extrapolated to the wider clinical community, creating a true shift in pediatric orthopaedic clinical practice throughout the country.

Intervention type: DEVICE
Group type: OTHER
Intervention: Hip Spica Cast
Description: Traditional spica casts, the current standard of care for diaphyseal femoral shaft fractures with minimal shortening in children age 0-5 years old. Although spica cast immobilization is standard of care for femur fractures in young children, caring for a child in a spica cast presents a significant socioeconomic burden on families and the healthcare system. Basic hygiene and transportation for a child in a spica cast requires burdensome adjustments for caretakers, as well as the added expenses of specialized car seats or transportation services. Improper spica cast care can lead to skin complications, additional visits for cast adjustments, or even revision casting in the operating room.
Study: NCT00649610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: diclofenac
Description: diclofenac 75 mg twice daily (BID) for 7 days
Study: NCT05283499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPIOID
Description: Analgesic assignment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NON-OPIOID
Description: Analgesic assignment
Study: NCT04722289

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Together on Diabetes
Description: Social and emotional support'; 'Assistance in daily management'; and 'Linkage to healthcare services'
Study: NCT01464398

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress reduction
Description: 8 weekly sessions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stress reduction with Health education
Description: 8 weekly sessions
Study: NCT00169767

Intervention type: OTHER
Intervention: Comparison study between KTP and HoLAP for BPH
Description: Comparison study between KTP and HoLAp for BPH
Study: NCT03908268

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Nurture Intervention (FNI)
Description: The mother-child pair will be asked to talk and play with each other as the pair customarily does. If the child becomes restless and dysregulated, the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comforting touch, soothing words and eye contact. Each dyad will attend eight group FNI sessions within sixteen weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Children's Learning Center (CLC) Program
Description: Typical, age-tailored CLC curriculum taught by CLC teachers. Children attend CLC as usual and parents do not take part in group sessions.
Study: NCT05732597

Intervention type: PROCEDURE
Intervention: Coronary angiography
Description: A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.

Intervention type: PROCEDURE
Intervention: Coronary angiography
Description: A coronary angiogram is a procedure that uses X-ray imaging to see the patient's blood vessels of the heart. The test is generally done to see if there's a restriction in blood flow going to the heart.
Study: NCT02353325

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-encapsulated FeSO4

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4, before cooking

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4, after cooking

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non-encapsulated FeSO4 + ascorbic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 + ascorbic acid, before cooking

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: encapsulated FeSO4 + ascorbic acid, after cooking
Study: NCT01381224

Intervention type: OTHER
Intervention: Observation of biomechanical effects post injection
Description: Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection